Pharmaceutical company · PFE

Pfizer
clinical trial
pipeline

Registry checked

Published

PF-08634404 is linked to 11 distinct active studies: 11 recruiting. Elranatamab is linked to 8 distinct active studies: 4 recruiting, 3 active but not recruiting, 1 not yet recruiting.

Phase 2 study NCT05995964 in Atopic Dermatitis lists estimated primary completion on 12 November 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

259active trials
as lead sponsor
  • Phase 145
  • Phase 242
  • Phase 395
  • Phase 410
  • Phase not recorded67

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

5935 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

03Primary completion

Primary completion moved earlier by 361 days

2027-12-08 (estimated)2026-12-12 (estimated)
08 Dec 202712 Dec 2026

A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults

NCT06994897 · ClinicalTrials.gov
Recorded by ComplyRx
31 Oct 2026
Registry last updated
30 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020000222
2026-10-031110032
2026-10-040000000
2026-10-051110031
2026-10-060000000
2026-10-074000044
2026-10-081000231
2026-10-091000011
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140100011
2026-10-151100022
2026-10-162110043
2026-10-171110031
2026-10-180000000
2026-10-190000000
2026-10-201000011
2026-10-213110054
2026-10-222211394
2026-10-230000000
2026-10-241220163
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-282110042
2026-10-290000000
2026-10-301000011
2026-10-312320074
Type totals241511185935 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

PF-08634404

Canonical investigational asset

11
Active trials
11
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 26
  • Phase 35
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Hepatocellular Carcinoma · Advanced Non-Small Cell Lung Cancer · Advanced or Metastatic Renal Cell Carcinoma
Next primary completion
18 October 2027 · estimated
Open drug

Elranatamab

ELREXFIO

8
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 12
  • Phase 20
  • Phase 34
  • Phase 42
  • Phase not recorded0
Studied condition
Multiple Myeloma · Relapsed/Refractory Multiple Myeloma
Next primary completion
04 August 2027 · estimated
Open drug

tucatinib

tukysa

8
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 11
  • Phase 23
  • Phase 33
  • Phase 41
  • Phase not recorded0
Studied condition
Advanced Non-Small Cell Lung Cancer · Biliary Tract Neoplasms · Breast Cancer
Next primary completion
Not reported
Open drug

MET097

Canonical investigational asset

7
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 13
  • Phase 21
  • Phase 33
  • Phase 40
  • Phase not recorded0
Studied condition
Diabetes, Type 2 · Drug Interaction · Healthy
Next primary completion
21 September 2027 · estimated
Open drug

Ritlecitinib

LITFULO

7
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 22
  • Phase 34
  • Phase 40
  • Phase not recorded1
Studied condition
Active Nonsegmental Vitiligo · Alopecia Areata · Chronic Spontaneous Urticaria
Next primary completion
08 December 2026 · estimated
Open drug

Rimegepant

NURTEC ODT

6
Active trials
5
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 35
  • Phase 41
  • Phase not recorded0
Studied condition
Acute Treatment of Migraine · Menstrual Migraine · Migraine
Next primary completion
29 November 2026 · estimated
Open drug

172 of 259 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 172 of 259 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Pfizer trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Tilrekimig

NCT05995964

Phase 2 · Active, not recruiting

Trial source and qualifications

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

5 candidate observations · 2 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

3 inspected observations omitted. At most three verified observations are shown, not full history.

  • status flip · Recorded 2026-10-24 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
  • enrollment change · Recorded 2026-10-24 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 22 Aug 2023 · actual
Primary completion: 12 Nov 2026 · estimated
Study completion: 01 Apr 2027 · estimated

2021202220232024202520262027202820292030
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Rimegepant

NCT06641466

Phase 3 · Recruiting

Trial source and qualifications

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

2 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 11 Mar 2025 · actual
    Primary completion: 29 Nov 2026 · estimated
    Study completion: 30 Mar 2027 · estimated

    2021202220232024202520262027202820292030
    B7981027
    Ritlecitinib higher dose

    NCT07029711

    Phase 3 · Active, not recruiting

    Trial source and qualifications

    A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

    4 candidate observations · 0 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    4 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 31 Jul 2025 · actual
      Primary completion: 02 Dec 2026 · estimated
      Study completion: 06 Jan 2027 · estimated

      2021202220232024202520262027202820292030
      A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine
      VLA15

      NCT07500506

      Phase 3 · Recruiting

      Trial source and qualifications

      A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

      1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      1 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 08 Apr 2026 · actual
        Primary completion: 04 Dec 2026 · estimated
        Study completion: 04 Dec 2026 · estimated

        2021202220232024202520262027202820292030
        A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
        Ritlecitinib

        NCT07228390

        Phase 2 · Active, not recruiting

        Trial source and qualifications

        A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

        3 candidate observations · 3 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        Up to three verified eligible observations in the bounded history window.

        • status flip · Recorded 2026-09-02 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
        • enrollment change · Recorded 2026-09-02 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
        • pc date moved · Recorded 2026-09-02 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

        Start: 13 Nov 2025 · actual
        Primary completion: 08 Dec 2026 · estimated
        Study completion: 05 Jan 2027 · estimated

        2021202220232024202520262027202820292030
        A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
        disitamab vedotin

        NCT04879329

        Phase 2 · Recruiting

        Trial source and qualifications

        A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

        0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        No eligible observations recorded in the inspected period.

          Start: 03 May 2022 · actual
          Primary completion: 11 Dec 2026 · estimated
          Study completion: 14 Apr 2029 · estimated

          2021202220232024202520262027202820292030

          Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

          6 selected of 99 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 24 actual primary completions, 0 untyped primary completions, 4 past estimates, 10 outside the horizon, 0 contradictory dates.

          04 / Therapeutic focus

          Where the activity is

          88

          active trials in Oncology

          Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

          Active trials by primary therapeutic area

          • Oncology88 trials
          • Infectious Disease22 trials
          • Metabolic/Endocrine/Nutrition19 trials
          • Dermatology18 trials
          • Neurology12 trials
          • Haematology8 trials
          • Respiratory8 trials
          • Immunology & Inflammation7 trials
          • Cardiovascular3 trials
          • Gastroenterology & Hepatology2 trials
          • Renal & Urology1 trials
          • Unmapped59 trials
          • Healthy volunteers12 trials

          Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

          06 / Related companies

          All companies

          Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

          Sources, scope and methodology

          ClinicalTrials.gov lead-sponsor scope

          Enumerated controlled company group covers 4,073 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Pfizer · Array BioPharma · Metsera, a wholly owned subsidiary of Pfizer. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion. Independent Biohaven is excluded.

          ClinicalTrials.gov

          Attribution coverage

          4,074 distinct registry candidates produced 4,073 accepted studies. 0 mapped to other owners, 1 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 21 unverified, 7 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

          Indexed enrichment

          3,438 scoped records have indexed enrichment and 635 do not. Missing enrichment does not remove a trial from cohort counts.

          Scope observation

          The successful attribution check completed at 2026-11-01T03:00:34.516Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 6e2a13327fdbc0a92dbbf7b6931c5cc5770fe8c5aeeb40d08348074daf0e82bf.

          Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

          Dated canonical-attribution snapshot: 4,073 mapped lead-sponsored clinical studies across all statuses. 3,438 have indexed enrichment, 635 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

          Keep following
          what matters.

          Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

          Build your watch

          Choose what to track in the watch builder.